Stefan Oelrich - Bayer AG Executive
BAYZF Stock | USD 23.55 0.11 0.46% |
Executive
Mr. Stefan Oelrich was Member of the Management Board, Head of the Pharmaceuticals Division of Bayer Aktiengesellschaft since November 1, 2018. After graduating from high school in Paris, France, he joined Bayer AG as a commercial trainee in 1989 and qualified as a commercial assistant in 1991. Over the next 20 years, he held a number of positions of increasing responsibility in the health care business in Latin America, Europe and the United States. In 1998, after working in Argentina and Uruguay, Mr. Oelrich transferred to headquarters in Leverkusen for two years before assuming responsibility for Pharmaceuticals in Belgium. Between 2003 and 2005, he was Vice President of Marketing at Pharmaceuticals in the United States. He was subsequently appointed President of Healthcare and Diagnostics in France. In 2006, Mr. Oelrich returned to the United States as Senior Vice President and General Manager of Womens Healthcare. In 2011, he joined Sanofi as General Manager in Germany, Switzerland and Austria. In 2015, Mr. Oelrich became head of Sanofis Diabetes and Cardiovascular business unit in Europe. At the same time, he served as Sanofi Europe Coordinator. In 2016, Mr. Oelrich became head of Sanofis global diabetes franchise. A year later, he was appointed Executive Vice President Diabetes Cardiovascular on the Executive Committee of Sanofi. Since 2016, Mr. Oelrich was Member of the Supervisory Board of the Berlin Institute of Health. since 2018.
Age | 55 |
Tenure | 7 years |
Phone | 49 214 30 1 |
Web | https://www.bayer.com |
Bayer AG Management Efficiency
The company has return on total asset (ROA) of 0.0576 % which means that it generated a profit of $0.0576 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.13 %, meaning that it generated $0.13 on every $100 dollars invested by stockholders. Bayer AG's management efficiency ratios could be used to measure how well Bayer AG manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Robert Cecutti | Magna International | N/A | |
Neha CPA | Brunswick | 49 | |
John Buelow | Brunswick | 53 | |
Sarah Archibong | Cars Inc | N/A | |
Tom Rucker | Magna International | N/A | |
Ulrich Kammholz | PACCAR Inc | N/A | |
Brent Dahl | Brunswick | N/A | |
Rousseau Jooste | Barrick Gold Corp | N/A | |
Samir Shah | Brunswick | N/A | |
Rodney Quick | Barrick Gold Corp | 48 | |
Sebastiaan Bock | Barrick Gold Corp | 46 | |
Michael Beers | PACCAR Inc | N/A | |
Poupak Bahamin | Barrick Gold Corp | 54 | |
Louis Tonelli | Magna International | N/A | |
John Steele | Barrick Gold Corp | 59 | |
Grant Beringer | Barrick Gold Corp | 43 | |
Angelique Marks | Cars Inc | 56 | |
James Rogers | Cars Inc | 67 | |
Lois Wark | Barrick Gold Corp | 69 | |
Sherry Siu | East Africa Metals | 55 | |
Tracy Fuerst | Magna International | N/A |
Management Performance
Return On Equity | 0.13 | |||
Return On Asset | 0.0576 |
Bayer AG Leadership Team
Elected by the shareholders, the Bayer AG's board of directors comprises two types of representatives: Bayer AG inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bayer. The board's role is to monitor Bayer AG's management team and ensure that shareholders' interests are well served. Bayer AG's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bayer AG's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sarena Lin, Labor Officer | ||
Oliver Maier, Head Relations | ||
Gabriel Harnier, Patents Law | ||
Heiko Schipper, Member of the Management Board, Head of the Consumer Health Division | ||
Rodrigo Santos, Member Division | ||
Michael Preuss, Gov Communications | ||
Stefan Oelrich, Member of the Management Board, Head of the Pharmaceuticals Division | ||
Wolfgang Nickl, CFO, Member of the Management Board | ||
BerndPeter Bier, Head Taxes | ||
Werner Baumann, Chief Strategy and Portfolio Officer and Member of Management Board |
Bayer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bayer AG a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.13 | |||
Return On Asset | 0.0576 | |||
Profit Margin | 0.09 % | |||
Operating Margin | 0.23 % | |||
Current Valuation | 87.41 B | |||
Shares Outstanding | 982.42 M | |||
Shares Owned By Institutions | 47.11 % | |||
Price To Earning | 321.83 X | |||
Price To Book | 1.36 X | |||
Price To Sales | 1.06 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Bayer Pink Sheet
Bayer AG financial ratios help investors to determine whether Bayer Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bayer with respect to the benefits of owning Bayer AG security.